Teva (TEVA) Pharmaceuticals “announced that Moody’s Investor Services has raised the company’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody’s report cites the Company’s strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva upgraded to Overweight from Neutral at JPMorgan
- Positive Outlook for Teva Pharmaceutical: Cost-Cutting Initiatives and Growth Potential Drive Buy Rating
- Teva price target raised to $22 from $20 at BofA
- Teva Pharmaceuticals: Positioned for Growth with Strategic Cost-Saving Initiatives and New Product Cycle
- Teva Reports Strong Q1 2025 Growth with Innovative Medicines